ACRV Insider Filing: Chief Legal Officer Withholds 184 Shares for Taxes

Rhea-AI Filing Summary

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on 08/14/2025 involving the company’s common stock. The filing shows 184 shares were disposed at a price of $1.39 per share.

The form states these shares were withheld by the issuer to satisfy a mandatory tax withholding obligation upon the vesting of restricted stock units. After the withholding, Ms. Miller beneficially owns 35,581 shares directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Positive

• Disclosure of tax-withholding on RSU vesting is explicit, clarifying the nature of the 184-share disposition
• Officer retains significant direct ownership with 35,581 shares after the withholding

Negative

• Shares were disposed (184 shares) to satisfy tax withholding, reducing the reporting person's share count
• Reported withholding value $1.39 may reflect a low per-share valuation used for tax purposes

Insights

Securities Analyst

TL;DR: Routine tax-withholding disposition after RSU vesting; small in size relative to ownership, no evident change in control.

The transaction code F(1) and the explanation confirm the 184-share disposition was a non-market event: shares were withheld by the issuer to satisfy tax withholding on vested restricted stock units. The per-share amount reported ($1.39) reflects the value used for withholding rather than an open-market sale. Post-transaction direct beneficial ownership is 35,581 shares, which indicates continued equity alignment with management. Materiality is low given the small share count.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting requirements; the filing documents routine compensation-related withholding.

The Form 4 properly identifies the reporting person, role

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		F(1)		184	D	$1.39	35,581	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mary Miller report on Form 4 for ACRV?

The filing reports a disposition of 184 shares on 08/14/2025 at a per-share amount of $1.39 related to tax withholding upon RSU vesting.

Why were the 184 shares disposed according to the Form 4?

The form explains the shares were withheld by the issuer to satisfy mandatory tax withholding on vested restricted stock units.

How many Acrivon shares does Mary Miller own after the transaction?

Following the reported transaction, Mary Miller beneficially owns 35,581 shares (direct).

When was the Form 4 signed for this transaction?

The Form 4 contains a signature by an attorney-in-fact dated 08/18/2025.

What is the reporting person's role at Acrivon Therapeutics?

Mary Miller is reported as the company’s Chief Legal Officer and an officer of the issuer.